Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody-CD38
- Genmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next-generation CD38 antibody product, HexaBody-CD38, incorporating Genmab?s proprietary HexaBody technology
- New agreement builds on Genmab?s successful DARZALEX??collaboration with Janssen
- Next-generation HexaBody-CD38 could potentially add to the DARZALEX multiple myeloma franchise and expand the potential of CD38-targeted therapies in further indications
Attachment